We investigated Tolvaptan efficacy and long-term prognosis with focus on nutrition in 20 patients with refractory hepatic ascites in hepatocellular carcinoma (HCC). Bloating improved in 55% of patients, as determined using a Japanese version of the Support Team Assessment Schedule. Nutritional status improved with Tolvaptan treatment, based on the Controlling Nutritional Status score and Onodera’s prognostic nutritional index. Long-term prognosis was better in responders than in non-responders (mean survival time: 308 days vs. 97 days, p = 0.031). Tolvaptan was even effective in many patients with HCC, with additional improvement in long-term prognosis expected with improvement in the nutritional status.
References
[1]
Sola, E., Watson, H., Graupera, .I, et al. (2012) Factors Related to Quality of Life in Patients with Cirrhosis and Ascites: Relevance of Serum Sodium Concentration and Leg Edema. Journal of Hepatology, 57, 1199-1206.
https://doi.org/10.1016/j.jhep.2012.07.020
[2]
Llach, J., Gines, P., Arroyo, V., et al. (1988) Prognostic Value of Arterial Pressure, Endogenous Vasoactive Systems, and Renal Function in Cirrhotic Patients Admitted to the Hospital for the Treatment of Ascites. Gastroenterology, 94, 482-487.
https://doi.org/10.1016/0016-5085(88)90441-6
[3]
Larramona, G.L., Lucendo, A.J. and Tenias, J.M. (2015) Association between Nutritional Screening via the Controlling Nutritional Status Index and Bone Mineral Density in Chronic Liver Disease of Various Etiologies. Hepatology Research, 45, 618-628. https://doi.org/10.1111/hepr.12395
[4]
Yamamura, Y., Nakamura, S., Itoh, S., et al. (1998) OPC-41061, a Highly Potent human Vasopressin V2-Receptor Antagonist: Pharmacological Profile and Aquaretic Effect by Single and Multiple Oral Dosing in Rats. Journal of Pharmacology and Experimental Therapeutics, 287, 860-867.
[5]
Ohki, T., Sato, K., Yamada, T., et al. (2015) Efficacy of Tolvaptan in Patients with Refractory Ascites in a Clinical Setting. World Journal of Hepatology, 7, 1685-1693.
https://doi.org/10.4254/wjh.v7.i12.1685
[6]
Sakaida, I., Kawazoe, S., Kajimura, K., et al. (2014) Tolvaptan for Improvement of Hepatic Edema: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Hepatology Research, 44, 73-82. https://doi.org/10.1111/hepr.12098
[7]
Sakaida, I., Terai, S., Kurosaki, M., et al. (2017) Effectiveness and Safety of Tolvaptan in Liver Cirrhosis Patients with Edema: Interim Results of Post-Marketing Surveillance of Tolvaptan in Liver Cirrhosis (START Study). Hepatology Research, 47, 1137-1146. https://doi.org/10.1111/hepr.12852
[8]
Miyashita, M., Matoba, K., Sasahara, T., et al. (2004) Reliability and Validity of Japanese Version STAS (STAS-J). Palliative and Supportive Care, 2, 379-384.
https://doi.org/10.1017/S1478951504040507
[9]
Hiramine, Y., Uojima, H., Nakanishi, H., et al. (2017) Response Criteria of Tolvaptan for the Treatment of Hepatic Edema. Journal of Gastroenterology.
[10]
Ignacio de Ulibarri, J., Gonzalez-Madrono, A., de Villar, N.G., et al. (2005) CONUT: A Tool for Controlling Nutritional Status. First Validation in a Hospital Population. Nutricion Hospitalaria, 20, 38-45.
[11]
Onodera, T., Goseki, N. and Kosaki, G. (1984) Prognostic Nutritional Index in Gastrointestinal surgery of Malnourished Cancer Patients. Nihon Geka Gakkai Zasshi, 85, 1001-1005.
[12]
The Liver Cancer Study Group of Japan Society of Hepatology (2015) The General Rules for the Clinical and Pathological Study of Primary Liver Cancer. 6th Edition, Kanehara & Co Ltd., Tokyo.
[13]
Pugh, R.N.H., Murray-Lyon, I.M., Dawson, J.L., et al. (1973) Transection of the Oesophagus for Bleeding Oesophageal Varices. British Journal of Surgery, 60, 646-649. https://doi.org/10.1002/bjs.1800600817
[14]
Shimada, M., Iwase, H., Hirashima, N., et al. (2017) Nutritional Status and Long-Term Prognosis in Patients with Refractory Hepatic Ascites Treated with Tolvaptan. Journal of Gastroenterology, Hepatology and Endoscopy, 2, 1-5.
https://doi.org/10.15761/GHE.1000131
[15]
Larramona, G.L., Lucendo, A.J. and Tenias, J.M. (2015) Association between Nutritional Screening via the Controlling Nutritional Status Index and Bone Mineral Density in Chronic Liver Disease of Various Etiologies. Hepatology Research, 45, 618-628. https://doi.org/10.1111/hepr.12395
